Overview
- Asundexian reduced recurrent strokes by about 26% versus placebo in more than 12,000 patients with prior non‑cardioembolic ischemic stroke or high‑risk TIA, given once daily on top of antiplatelet therapy.
- No increase in major ISTH bleeding was observed compared with placebo, and rates of other bleeding outcomes were similar between groups.
- Detailed results were presented at a medical conference in New Orleans, refining earlier positive signals from the Oceanic‑Stroke program.
- Bayer intends to submit the data to health authorities and already holds U.S. Fast‑Track status for certain stroke patients.
- Analysts peg potential peak sales in the €1–2 billion range in a roughly €3 billion market, though final uptake will hinge on rival data such as Milvexian results expected in late 2026 to early 2027.